ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

Risk of Adverse Outcomes Due to COVID-19 May Be Lower with TNF Inhibitor Monotherapy

Katie Robinson  |  May 5, 2022

Findings support the continued use of TNF inhibitor monotherapy in individuals with immune-mediated inflammatory diseases. In the study, these patients had a lower risk of hospitalization or death caused by COVID-19 than patients on other commonly prescribed treatment regimens

Filed under:Conditions Tagged with:COVID-19COVID-19 Global Rheumatology Allianceimmune-mediated inflammatory diseases (IMIDs)monotherapyTNF inhibitors

New Tech Provides Insights Into the Pathogenesis of Psoriatic Arthritis

Maria de la Luz Garcia-Hernandez, PhD, & Christopher Ritchlin, MD, MPH  |  May 5, 2022

The etiology of psoriatic arthritis (PsA) is poorly understood but current evidence supports an interaction between genetic and environmental factors that coalesce to promote local tissue inflammation.1-3 The pivotal cytokines that underlie the local inflammatory response in a wide range of tissues are interleukin (IL) 23, IL-17 and tumor necrosis factor (TNF).4 The central contribution…

Filed under:ConditionsPsoriatic Arthritis Tagged with:Psoriatic Arthritis

Looking to Psoriatic Arthritis History to Disrupt Current Thinking

Rebecca H. Haberman, MD, & Jose U. Scher, MD  |  May 4, 2022

As the cloud moved away from the tent, Miriam’s skin suddenly became diseased, as white as snow. When Aaron turned toward her, he saw that she was diseased. —Numbers 12:10 For 29 years he [Fray Pedro de Urraca] was afflicted by … pain, suffering it at once in all the joints of his body, with…

Filed under:ConditionsPsoriatic Arthritis Tagged with:Psoriatic Arthritis

FDA Approves Risankizumab-rzaa for PsA

Michele B. Kaufman, PharmD, BCGP  |  April 20, 2022

Two recent trials demonstrated the safety and efficacy of risankizumab-rzaa for the treatment of adults with active psoriatic arthritis.

Filed under:Biologics/DMARDsDrug Updates Tagged with:FDA approvalPsAPsoriatic Arthritisrisankizumab-rzaaU.S. Food and Drug Administration (FDA)

Real-Life Rheumatology: Clinical Pearls for Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  March 23, 2022

At the 17th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases meeting, Ana-Maria Orbai, MD, MHS, discussed lessons learned from the cases of several patients with psoriatic arthritis.

Filed under:ConditionsMeeting ReportsPsoriatic Arthritis Tagged with:Advances in the Diagnosis and Treatment of the Rheumatic Diseases meetingClinical RheumatologyPractice PearlsPsoriatic Arthritis

Spring 2022’s Awards, Appointments & Announcements in Rheumatology

Gretchen Henkel  |  March 14, 2022

Martin Kriegel, MD, PhD, Receives 2021 Lupus Insight Award “I have always found the conundrum of autoimmunity interesting. It’s fascinating to find out why the immune system attacks the body, how it can distinguish self from non-self,” says Martin Kriegel, MD, PhD, head of the Department of Translational Rheumatology & Immunology, Institute of Musculoskeletal Medicine,…

Filed under:Awards Tagged with:Dr. Christopher T. RitchlinDr. Mariana J. KaplanDr. Martin Kriegel

Stmool / shutterstock.com

How to Avoid Cognitive Errors in Rheumatology

Megan Milne, MD, & Rebecca E. Sadun, MD, PhD  |  March 14, 2022

The 1999 Institute of Medicine report To Err Is Human gave a sobering depiction of the magnitude and consequences of medical error.1 The report concluded that approximately 98,000 people die in hospitals annually due to preventable medical errors. Of all the errors detailed in this report, diagnostic errors have since been determined to be the…

Filed under:Professional Topics Tagged with:best practicesbiascognitive errorsErrorsmedical errors

Andrew Brookes / Image Source on Offset

Clinical Insights into Axial Spondyloarthritis: Rheumatology Drugs at a Glance, Part 5

Mary Choy, PharmD, BCGP, FASHP  |  February 10, 2022

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options; others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Filed under:Axial SpondyloarthritisBiologics/DMARDsConditionsDrug Updates Tagged with:Ankylosing SpondylitisAS Resource Center

How Do Axial SpA & PsA with Axial Involvement Differ?

Samantha C. Shapiro, MD  |  February 2, 2022

The differences between axial spondyloarthropathy (axSpA) and axial involvement in psoriatic arthritis (axPsA) have clinical and therapeutic implications. Three experts discussed the distinctions during ACR Convergence 2021.

Filed under:ACR ConvergenceAxial SpondyloarthritisConditionsMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2021axial spondyloarthritis (SpA)axial spondyloarthropathyPsoriatic Arthritis

New Data Highlight Effectiveness of Guselkumab for Patients with PsA

Michele B. Kaufman, PharmD, BCGP  |  February 2, 2022

The use of guselkumab improved joint and skin symptoms in biologic naive patients with PsA, according to research presented during ACR Convergence 2021.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2021guselkumabPsAPsoriatic Arthritis

  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences